Vemurafenib (9) (N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide) is a selective inhibitor of BRAFV600E-mutated kinase, resulting in the inhibition of tumor cells overexpressing this mutation in the RAF/MEK/ERK signaling pathway. Here, MAPK1 is linked to neoplasm.